GSK plc (LON:GSK) Insider Buys £129.84 in Stock

GSK plc (LON:GSK) insider Julie Brown bought 8 shares of the stock in a transaction on Tuesday, June 11th. The shares were bought at an average price of GBX 1,623 ($20.67) per share, for a total transaction of £129.84 ($165.34).

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,604.50 ($20.43) on Friday. The firm has a market capitalization of £65.46 billion, a PE ratio of 1,472.02, a P/E/G ratio of 1.19 and a beta of 0.27. GSK plc has a 12 month low of GBX 1,302.60 ($16.59) and a 12 month high of GBX 1,823.50 ($23.22). The company has a debt-to-equity ratio of 134.34, a current ratio of 0.87 and a quick ratio of 0.73. The business has a 50-day moving average of GBX 1,690.77 and a two-hundred day moving average of GBX 1,618.77.

GSK Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, July 11th. Investors of record on Thursday, May 16th will be issued a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, May 16th. This represents a yield of 0.9%. GSK’s payout ratio is 5,504.59%.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of analyst reports. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Tuesday, June 4th. Barclays reissued an “equal weight” rating and set a GBX 1,725 ($21.97) price objective on shares of GSK in a research note on Tuesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 ($24.83) target price on shares of GSK in a research note on Wednesday, April 17th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.34).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.